NCT01371799View on ClinicalTrials.gov

A Study to Examine the Pharmacodynamic Effects of GSK1034702 on Neurophysiological Biomarkers of Cognition in Nicotine Abstained Otherwise Healthy Smokers

PHASE1CompletedINTERVENTIONAL
Enrollment

9

Participants

Timeline

Start Date

December 17, 2009

Primary Completion Date

June 18, 2010

Study Completion Date

June 18, 2010

Conditions
Mental Disorders
Interventions
DRUG

Drug

Placebo

DRUG

Drug

4mg and 8mg Study drug

Trial Locations (1)

CB2 2GG

GSK Investigational Site, Cambridge

Sponsors

Lead Sponsor

GlaxoSmithKline
All Listed Sponsors
lead

GlaxoSmithKline

INDUSTRY

NCT01371799 - A Study to Examine the Pharmacodynamic Effects of GSK1034702 on Neurophysiological Biomarkers of Cognition in Nicotine Abstained Otherwise Healthy Smokers | Biotech Hunter | Biotech Hunter